|
What's New
Vasomedical, Inc. Donates 1,096 Pounds Of Food/Household Goods To The LI Cares Food Bank EECP Newsletter - EECP® As An Effective Treatment Of Heart Failure - Volume 2, Issue 2 Vasomedical Launches New Products at the AHA Scientific Sessions 2009 EECP® Therapy Symposium at the Great Wall International Congress of Cardiology 2009 Vasomedical Reports Profit First Quarter Fiscal Year 2010 Financial Results |
Product Overview
Why Vasomedical’s EECP® ? In a sentence... It’s Good Medicine and Good Business. Counterpulsation is a treatment method to increase blood flow in the body and reduce workload of the heart. External counterpulsation (ECP) is a term used to describe systems using a single hydraulic chamber wrapped around the lower extremities. Pressure is applied to the chamber during cardiac diastolic relaxation phase and removed during ejection systolic phase. The devices were inefficient and difficult to use. During the past 15 years, technological and clinical advancement led to the development of EECP® - Enhanced External Counterpulsation, the therapeutic systems exclusively designed and manufactured by Vasomedical with sequential pneumatic compression to increase retrograde diastolic flow, venous return and systolic unloading, greatly improve the ease of use, patient safety and clinical effectiveness. EECP® (Enhanced External Counterpulsation) systems are FDA cleared non-invasive medical devices used as an adjunctive treatment for patients who suffer from coronary artery disease or ischemic heart failure. CMS (Centers for Medicare and Medicaid Services) reimbursement coverage has been provided for the use of ECP since 1999 for patients who have been diagnosed with disabling angina (Class III or Class IV, Canadian Cardiovascular Society Classification or equivalent classification) and whom are not readily amendable for interventional procedures. EECP® therapy is a low-risk, cost-effective option for patients who suffer from coronary artery disease and its associated symptoms. The specific features of Vasomedical’s EECP systems are: • Clinical proven, evidence-based therapeutic systems documenting the effectiveness and safety of EECP® in the treatment of patients with coronary heart disease with: › More than 150 published papers in world renounced medical journals Only Vasomedical’s EECP® therapy is supported by randomized, controlled clinical studies published in peer reviewed medical journals. Most other manufacturers of external counterpulsation devices don’t have any published clinical evidence showing the efficacy of their device. • Proprietary technologies with specific design providing safety and effectiveness with › Specific electronic circuitry to reduce motion artifacts in provide stable triggering signals to operate in synchronization with each cardiac cycle • Specific Training and Service Programs › Expert certified quality operation training program to ensure safe and effective delivery of EECP® therapy Vasomedical’s EECP® systems are the only systems that have been designed with years of research based upon real world technical and clinical know-how and we will continue to be the world market leader in providing noninvasive, safe and effective treatment to patients with cardiovascular disease. Vasomedical EECP® Therapy
Vasomedical offers four unique EECP therapy systems. Learn more about each one.
|